Mantovani Cinthia de Carvalho, Silva Jefferson Pereira E, Forster Guilherme, Almeida Rafael Menck de, Diniz Edna Maria de Albuquerque, Yonamine Mauricio
Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 580, 13B, 05508-900 São Paulo, SP, Brazil.
Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, Av. Prof. Lineu Prestes 580, 13B, 05508-900 São Paulo, SP, Brazil.
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Feb 1;1074-1075:1-7. doi: 10.1016/j.jchromb.2018.01.009. Epub 2018 Jan 7.
Cannabis misuse during pregnancy is associated with severe impacts on the mother and baby health, such as newborn low birth weight, growth restriction, pre-term birth, neurobehavioral and developmental deficits. In most of the cases, drug abuse is omitted or denied by the mothers. Thus, toxicological analyzes using maternal-fetal matrices takes place as a suitable tool to assess drug use. Herein, meconium was the chosen matrix to evaluate cannabis exposure through identification and quantification of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic (THCCOOH). Accelerated solvent extraction (ASE) was applied for sample preparation technique to simultaneously extract and hydrolyze conjugated THCCOOH from meconium, followed by a solid-phase extraction (SPE) procedure. The method was developed and validated for gas chromatography-mass spectrometry (GC-MS), reaching hydrolysis efficiency of 98%. Limits of detection (LOD) and quantification (LOQ) were, respectively, 5 and 10 ng/g. The range of linearity was LOQ to 500 ng/g. Inter and intra-batch coefficients of variation were <8.4% for all concentration levels. Accuracy was in 101.7-108.9% range. Recovery was on average 60.3%. Carryover effect was not observed. The procedure was applied in six meconium samples from babies whose mothers were drug users and showed satisfactory performance to confirm fetal cannabis exposure.
孕期滥用大麻会对母婴健康产生严重影响，如新生儿低出生体重、生长受限、早产、神经行为和发育缺陷。在大多数情况下，母亲会隐瞒或否认药物滥用情况。因此，使用母胎基质进行毒理学分析成为评估药物使用的合适工具。在此，胎粪被选为评估大麻暴露的基质，通过鉴定和定量11-去甲-Δ9-四氢大麻酚-9-羧酸（THCCOOH）来实现。采用加速溶剂萃取（ASE）进行样品制备技术，以同时从胎粪中萃取并水解结合型THCCOOH，随后进行固相萃取（SPE）程序。该方法针对气相色谱-质谱联用（GC-MS）进行了开发和验证，水解效率达到98%。检测限（LOD）和定量限（LOQ）分别为5和10 ng/g。线性范围为LOQ至500 ng/g。所有浓度水平的批间和批内变异系数均<8.4%。准确度在101.7 - 108.9%范围内。回收率平均为60.3%。未观察到残留效应。该程序应用于来自母亲为吸毒者的婴儿的六个胎粪样本，在确认胎儿大麻暴露方面表现令人满意。
